Chiara Lazzari Selected Research

Chiara Lazzari Research Topics

Disease

29	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 01/2009
20	Neoplasms (Cancer) 04/2022 - 01/2005
8	Lung Neoplasms (Lung Cancer) 04/2022 - 08/2014
4	Disease Progression 11/2021 - 09/2013
3	Brain Neoplasms (Brain Tumor) 09/2021 - 01/2016
2	Neoplasm Metastasis (Metastasis) 04/2022 - 09/2021
2	Melanoma (Melanoma, Malignant) 09/2021 - 01/2014
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2018 - 10/2018
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2015 - 01/2014
1	Inflammation (Inflammations) 03/2021
1	Acute-Phase Reaction 03/2021
1	Bell Palsy (Bell's Palsy) 03/2019
1	Myasthenia Gravis 03/2019
1	Nervous System Diseases (Neurological Disorders) 03/2019
1	Polyneuropathies (Polyneuropathy) 03/2019
1	Brain Diseases (Brain Disorder) 03/2019
1	Circulating Neoplastic Cells 04/2018
1	Bradycardia 01/2015
1	Fatigue 01/2015
1	Edema (Dropsy) 01/2015
1	Vision Disorders (Hemeralopia) 01/2015
1	Cardiotoxicity 01/2015
1	Neutropenia 06/2014
1	Thymoma (Thymic Carcinoma) 01/2014
1	Adenocarcinoma 09/2013
1	Ataxia (Dyssynergia) 08/2009
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2009
1	Colorectal Neoplasms (Colorectal Cancer) 01/2009

Drug/Important Bio-Agent (IBA)

10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2009
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2012
5	Biomarkers (Surrogate Marker)IBA 03/2021 - 06/2014
5	Immune Checkpoint InhibitorsIBA 09/2020 - 01/2017
4	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2015
4	CrizotinibIBA 01/2016 - 03/2014
3	osimertinibIBA 04/2022 - 04/2018
3	Biological ProductsIBA 04/2021 - 02/2016
3	Circulating Tumor DNAIBA 01/2019 - 04/2018
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2015 - 06/2014
2	Proteins (Proteins, Gene)FDA Link 04/2021 - 08/2009
2	Imatinib Mesylate (Gleevec)FDA Link 01/2015 - 01/2014
2	Phosphotransferases (Kinase)IBA 01/2015 - 08/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	AutoantibodiesIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 11/2021
1	AntibodiesIBA 01/2021
1	NivolumabIBA 03/2019
1	SuspensionsIBA 03/2019
1	pembrolizumabIBA 03/2019
1	Temozolomide (Temodar)FDA LinkGeneric 12/2018
1	veliparibIBA 12/2018
1	RNA (Ribonucleic Acid)IBA 11/2018
1	Epidermal Growth Factor (EGF)IBA 11/2018
1	PlatinumIBA 10/2018
1	human CNGRC fusion protein tumor necrosis factor-alphaIBA 10/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2018
1	B7-H1 AntigenIBA 01/2018
1	LigandsIBA 02/2017
1	Angiogenesis InhibitorsIBA 01/2017
1	ChromatinIBA 02/2016
1	ceritinibIBA 06/2015
1	EGF Family of ProteinsIBA 02/2015
1	EnzymesIBA 01/2015
1	AfatinibIBA 08/2014
1	Gefitinib (Iressa)FDA Link 08/2014
1	Sorafenib (BAY 43-9006)FDA Link 01/2014
1	Protein Kinases (Protein Kinase)IBA 07/2009
1	Integrin beta4IBA 07/2009
1	Integrin alpha6beta4IBA 07/2009
1	Monoclonal AntibodiesIBA 01/2009
1	Pyrimidine DimersIBA 01/2005

Therapy/Procedure

10	Therapeutics 04/2022 - 09/2013
8	Drug Therapy (Chemotherapy) 01/2022 - 06/2014
6	Immunotherapy 09/2021 - 01/2017
2	Radiotherapy 01/2018 - 09/2013
1	Craniotomy 04/2022
1	Lymph Node Excision (Lymph Node Dissection) 04/2022
1	Combined Modality Therapy 04/2022
1	Precision Medicine 01/2021
1	Aftercare (After-Treatment) 12/2012
1	Lasers (Laser) 01/2012